T 0126/17 of 25.02.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T012617.20220225
- Date of decision
- 25 February 2022
- Case number
- T 0126/17
- Petition for review of
- -
- Application number
- 04754383.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- USE OF HIF ALPHA STABILIZERS FOR ENHANCING ERYTHROPOIESIS
- Applicant name
- Fibrogen, Inc.
- Opponent name
- Akebia Therapeutics, Inc.
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(b)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Grounds for opposition - insufficiency of disclosure (no)
Novelty - (yes)
Inventive step - (yes)
Inventive step - auxiliary request - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
Claims 1 to 27 of auxiliary request A filed during the oral proceedings on 25 February 2022.